USPTO trademark

HELIVARA

Opposition periodUSPTOWord markClass 5

"HELIVARA" is a word mark owned by Veloxis Pharmaceuticals, Inc., filed at the USPTO on June 3, 2026. It is in its opposition period and covers class 5 (Pharmaceuticals).

View Veloxis Pharmaceuticals, Inc. portfolioGet this data via the API
Official USPTO record
HELIVARA trademark as filed
As filed with the USPTO
Status
Opposition period
Since October 27, 2026
Filed
June 3, 2026
Registered
Not yet
Expires
Not recorded
Application no.
99862060
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
1 class
Ownership

Who owns HELIVARA

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Veloxis Pharmaceuticals, Inc.

Cary, United States

13 trademarks in the portfolioView company

Representative

Julia Anne Matheson

Potomac Law Group, PLLC

Goods and services

What the mark covers

The products and services HELIVARA is filed for, grouped by Nice class.

  • Pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of physical ailments; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of for skin wounds; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of for the treatment of burns; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of cardiovascular disease and cerebrovascular disease; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of neurological disease; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of cancer; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of osteoporosis; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of infectious diseases; pharmaceutical, peptide, and biologic preparations for the treatment of rheumatism; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of fever blisters; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of autoimmune diseases; pharmaceutical, peptide, and biologic preparations for the treatment of inflammation immunology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of organ transplant; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of pain; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of rare diseases; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of digestive diseases; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of hematologic disorders; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of kidney diseases; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of disease with immunosuppression; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in urology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in rheumatology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in nephrology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in organ transplant; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in hematology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in orthopedic medicine; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in pulmonology; drug delivery agents in the form of solutions, compounds, powders, and tablets that facilitate delivery of a wide range of pharmaceuticals, peptides, and biologics

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Official gazette publication confirmation e-mailed
  2. Published for opposition
  3. Notification of notice of publication e-mailed
  4. Approved for pub - principal register
  5. Assigned to examiner
  6. New application office supplied data entered
  7. Application filing receipt mailed
  8. New application entered
FAQ

About HELIVARA

Who owns the trademark "HELIVARA"?

The USPTO trademark "HELIVARA" (application 99862060) is owned by Veloxis Pharmaceuticals, Inc.

What is the status of "HELIVARA"?

Its status at the USPTO is: opposition period.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull HELIVARA and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019e9633-61d0-7678-9008-9de6ee746d43
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019e9633-61d0-7678-9008-9de6ee746d43",
  "object": "trademark",
  "mark_text": "HELIVARA",
  "status": {
    "primary": "pending",
    "stage": "pending_opposition"
  },
  "office_code": "US",
  "application_number": "99862060",
  "filing_date": "2026-06-03",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Veloxis Pharmaceuticals, Inc.",
      "entity_id": "ent_019eb70d-9d29-7010-afb1-780b1aaac666"
    }
  ]
}